Minnesota hospitals brace for potential cuts after Senate passes Trump's "big, beautiful bill"
In response, protesters rallied outside the state health department in St. Paul. They demonstrated against what could be more than $1 trillion in cuts to programs like Medicaid.
At Hennepin Healthcare, nearly 100,000 people use that insurance option.
"I am kind of shocked to be honest," Joel Williams, a Medicaid user, said.
Williams served as a Chicago police officer for 25 years. He is now disabled with severe asthma, is a kidney transplant recipient and he depends on Medicaid and Medicare.
When asked if he was scared about cuts, Williams said, "Definitely. This is major, this is major major. I never thought after years of working... It's unbelievable to me. I'm trying to grasp it."
Interim Hennepin Healthcare CEO Dr. Thomas Klemond is also scared.
"We are looking at 100 million or more potential losses," Klemond said. "These are projections and the bills are still evolving. We are looking at, can we keep doing what we are doing?"
Klemond says as Minnesota's largest safety net hospital, they will continue to treat everyone regardless of ability to pay. He adds that as people lose insurance, emergency room visits will soar. That means other hospital programs, even Hennepin Healthcare's renowned poison center and its burn unit, could be eyed for cuts. Klemond said.
"Can we continue doing all of the things we are doing? Can we continue doing most of the things we are doing? Can we survive?" Klemond said.
At Hennepin Healthcare and at hospitals around the state and country, this latest vote just raises the level of uncertainty over how they are going to be able to care for patients in the future.
Klemond says he expects to start losing Medicaid reimbursements as soon as January 2026 in Minneapolis.
There are concerns that some hospitals in small communities will close down altogether. The major health provider for rural Minnesota says they're still processing what is in the bill.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
A record-low 54% of U.S. adults say they drink alcohol, new poll shows
Fewer Americans are reporting that they drink alcohol amid a growing belief that even moderate alcohol consumption is a health risk, according to a Gallup poll released Wednesday. The survey finds that 54% of U.S. adults say they drink alcoholic beverages such as liquor, wine or beer — "the lowest by one percentage point in Gallup's nearly 90-year trend," the analytics company says. And a record high percentage of U.S. adults, 53%, now say moderate drinking is bad for their health, up from 28% in 2015. The uptick in doubt about alcohol's benefits is largely driven by young adults — the age group that is most likely to believe drinking "one or two drinks a day" can cause health hazards — but older adults are also now increasingly likely to think moderate drinking carries risks. The findings of the poll, which was conducted in July, indicate that after years of many believing that moderate drinking was harmless — or even beneficial — worries about alcohol consumption are taking hold. According to Gallup's data, even those who consume alcohol are drinking less. The federal government is updating new dietary guidelines, including those around alcohol. Before the COVID-19 pandemic, government data showed U.S. alcohol consumption was trending up. But other government surveys have shown a decline in certain types of drinking, particularly among teenagers and young adults. This comes alongside a new drumbeat of information about alcohol's risks. While moderate drinking was once thought to have benefits for heart health, health professionals in recent years have pointed to overwhelming evidence that alcohol consumption leads to negative health outcomes and is a leading cause of cancer. Additionally, there are other factors contributing to the changing perspectives around alcohol, Willa Bennett, editor-in-chief of Cosmopolitan and Seventeen, said on "CBS Mornings Plus" Wednesday. "We know this generation is increasingly out in the world trying to find real community and camaraderie," Bennett said. People don't seem to need alcohol to go out anymore, she said. Other factors include less stigma around not drinking and the prevalence of social media. "People do want control of their image," Bennett said. "People don't want to give that up. It's scary. What are the long term risks?" Growing skepticism about alcohol's benefits Younger adults have been quicker than older Americans to accept that drinking is harmful, but older adults are coming around to the same view. About two-thirds of 18- to 34-year-olds believe moderate drinking is unhealthy, according to the poll, up from about 4 in 10 in 2015. Older adults are less likely to see alcohol as harmful — about half of Americans age 55 or older believe this — but that's a substantial increase, too. In 2015, only about 2 in 10 adults age 55 or older thought alcohol was bad for their health. In the past, moderate drinking was thought to have some benefits. That idea came from imperfect studies that largely didn't include younger people and couldn't prove cause and effect. Now the scientific consensus has shifted, and several countries recently lowered their alcohol consumption recommendations. Earlier this year, the outgoing U.S. surgeon general, Vivek Murthy, recommended a label on bottles of beer, wine and liquor that would clearly outline the link between alcohol consumption and cancer. "Alcohol is a well-established, preventable cause of cancer responsible for about 100,000 cases of cancer and 20,000 cancer deaths annually in the United States — greater than the 13,500 alcohol-associated traffic crash fatalities per year in the U.S. — yet the majority of Americans are unaware of this risk," Murthy said in a statement in January. The federal government's current dietary guidelines recommend Americans not drink or, if they do consume alcohol, men should limit themselves to two drinks a day or fewer while women should stick to one or fewer. Gallup's director of U.S. social research, Lydia Saad, said shifting health advice throughout older Americans' lives may be a reason they have been more gradual than young adults to recognize alcohol as harmful. "Older folks may be a little more hardened in terms of the whiplash that they get with recommendations," Saad said. "It may take them a little longer to absorb or accept the information. Whereas, for young folks, this is the environment that they've grown up in ... in many cases, it would be the first thing young adults would have heard as they were coming into adulthood." The government is expected to release new guidelines later this year, under the directive of health secretary Robert F. Kennedy Jr., who has promised big changes. Kennedy has not hinted at how the alcohol recommendations may shift. Drinking rates fall to decade low Slightly more than half of Americans, 54%, report that they drink alcohol — a low in Gallup's data that is especially pronounced among women and young adults. The previous low was 55%, recorded in 1958. "Declines in alcohol consumption do not appear to be caused by people shifting to other mood-altering substances — in particular, recreational marijuana, which is now legal in about half of U.S. states," Gallup said in a news release. "Although marijuana use is higher today than a decade ago, it has been fairly steady over the past four years and thus doesn't appear to be a factor in people choosing not to drink alcohol." Gallup says it has been tracking Americans' drinking behavior since 1939. Since 2001, it has tracked their views on health implications related to moderate drinking. Young Americans' alcohol consumption has been trending downward for years, accelerating the overall decline in alcohol consumption. In sharp contrast with Gallup's findings two decades ago, when young adults were likeliest to report drinking, young adults' drinking rate is now slightly below middle-aged and older adults. Americans' reported drinking is among the lowest since the question was first asked in 1939. For most of the last few decades, at least 6 in 10 Americans have reported drinking alcoholic beverages, only dipping below that point a few times in the question's history. Americans who drink alcohol are consuming less Even if concerns about health risks aren't causing some adults to give up alcohol entirely, these worries could be influencing how often they drink. The survey found that adults who think moderate drinking is bad for one's health are just as likely as people who don't share those concerns to report that they drink, but fewer of the people with health worries had consumed alcohol recently. About half of those who worry moderate drinking is unhealthy said they had a drink in the previous week, compared with about 7 in 10 who did not think drinking was bad for their health. Overall, only about one-quarter of Americans who drink said they had consumed alcohol in the prior 24 hours, a record low in the survey. Roughly 4 in 10 said that it had been more than a week since they had poured a drink. Trump sounds off on potential security guarantees for Ukraine Russia responds to potential Ukraine security guarantees as Trump signals U.S. support Celia Rose Gooding takes on Uhura's legacy in "Star Trek: Strange New Worlds" Solve the daily Crossword
Yahoo
15 minutes ago
- Yahoo
Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever
Key Points The average healthcare stock is yielding a fairly modest 1.8% these days. Medtronic has a historically high yield and a long history of raising its dividend. Alexandria Real Estate's yield is ultra-high, and it has plenty of dividend coverage. 10 stocks we like better than Medtronic › The average healthcare stock has a yield of just 1.8%, which isn't much to write home about today. You can do much better than that with Medtronic (NYSE: MDT), currently yielding 3%, or if you're really income-hungry, Alexandria Real Estate Equities (NYSE: ARE), now at 6.9%. Here's why these two high-yield healthcare stocks could be buy-and-hold candidates for your income portfolio right now. Medtronic is moving in the right direction A $1,000 investment in Medtronic will get you around 10 shares of the medical device giant. It has operations in the cardiovascular, neuroscience, medical-surgical, and diabetes arenas, and is a major player in every niche in which it operates. It also has a long history of success that's highlighted by the company's 48-year streak of annual dividend increases, which puts it just two years away from Dividend King status. That dividend streak is really important because it shows that Medtronic knows how to survive through both good and bad times. Indeed, a company can't create a record like that without having successfully muddled through a few rough patches. The 3% dividend yield is historically high today, which signals that Medtronic is going through another rough patch. What's happening right now, however, isn't unusual. Medtronic's business is heavily dependent on research and development. R&D is notoriously lumpy, and recent years haven't been great for new product launches. But new products are starting to get introduced, which should help boost growth. Meanwhile, costs have become an issue. It's normal for a large company to experience bloat, and Medtronic is looking to slim down and refocus around its most profitable businesses; the next big move is the spinoff of its diabetes business in 2026. The move is expected to be accretive in the first year, highlighting management's focus on profitability. In other words, Medtronic is doing what it should be doing -- and that is what it has long done as a business. If you have a buy-and-hold mentality, putting $1,000 to work in Medtronic today could be a great long-term investment choice. Alexandria is an industry-leading healthcare landlord You can buy around 12 shares of Alexandria Real Estate Equities with $1,000. It's a real estate investment trust (REIT) that focuses on owning medical offices. But that description doesn't do it justice, because those medical offices are highly specialized around medical research. They're vastly different from doctors' offices, given the technology needed to support healthcare research and development. Alexandria has long focused on building clusters -- a number of buildings located near each other -- in areas where medical research is a major industry. That helps with costs, and also helped to solidify the REIT as a leading property owner in its chosen niche. That said, Alexandria is in a bit of a transition period right now, as it looks to slim down to its best assets amid a broader slowdown in the medical-office space. A few large move-outs have also hampered results, with occupancy down to roughly 91% at the end of the second quarter of 2025, from about 95% at the end of 2024. Investors are worried, which isn't unreasonable, since adjusted funds from operations (FFO) per share fell slightly year over year in the second quarter. Still, the $2.33 per share in adjusted FFO is more than enough to cover the $1.32 per share in quarterly dividends. While it's true that office space requires more cash investment than many other property types, there is material leeway for adversity for Alexandria. And given that the dividend has been increased annually for 15 straight years, it seems highly likely that the board will look to support the dividend through this weak patch. Note, too, that the balance sheet is in very strong shape and the company doesn't have any material near-term debt maturities on the horizon. If you don't mind buying when others are fearful, this REIT looks like an attractive income opportunity. The right time to buy is often the hard time to buy It's easy to buy stocks that everybody loves, but just following the crowd can lead to bad investment choices. That's why it often pays to go down a less crowded path, buying well-run businesses when they're facing hard times. That's exactly the case with both Medtronic and Alexandria Real Estate Equities today. History suggests that both have a good chance of breaking out of their current funk. And that makes them strong buy-and-hold investment choices for long-term dividend investors. Should you buy stock in Medtronic right now? Before you buy stock in Medtronic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medtronic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $654,781!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,076,588!* Now, it's worth noting Stock Advisor's total average return is 1,055% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Reuben Gregg Brewer has positions in Medtronic. The Motley Fool has positions in and recommends Alexandria Real Estate Equities. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
15 minutes ago
- Yahoo
Digital Health In Neurology Market to Surpass Valuation of US$ 229.5 Billion By 2033
The market is rapidly advancing, driven by sophisticated software and empowered patients. This synergy is fostering a more personalized, accessible, and data-informed approach to managing complex neurological conditions worldwide. Chicago, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The global digital health in neurology market was valued at US$ 38.9 billion in 2024 and is expected to reach US$ 229.5 billion by 2033, growing at a CAGR of 21.8% during the forecast period 2025–2033. Digital therapeutics (DTx) are emerging as a powerful new class of medicine. These software-based interventions deliver evidence-based therapeutic programs directly to patients. In the area of ADHD, Akili Interactive's EndeavorOTC is making significant inroads. A 2024 registry study revealed that 58.2% of its users reported having combined type ADHD. The data also highlighted significant comorbidities, with 69% of users reporting depression and 56% reporting an anxiety disorder. A remarkable 87% of users stated they had no to moderate symptom control with their existing ADHD treatments. For a quarter of users, difficulties in obtaining their medication prompted them to try EndeavorOTC in the digital health in neurology market. Download Sample Pages: Another innovation, the Revibe smartwatch for children with ADHD, demonstrated its efficacy in a study with 706 participants. Children using the device showed a more than 25-minute increase in attention span after just three weeks. The study also recorded a 19% increase in on-task behaviors. Further validation for EndeavorOTC came from a 2024 study of 220 adults, which found clear improvements in ADHD-related symptoms and overall quality of life. An earlier 2021 study of EndeavorRx for children with ADHD showed that after two months, over two-thirds of the 206 participants' parents reported improvements in their child's ADHD-related impairments. Key Findings in Digital Health in Neurology Market Market Forecast (2033) US$ 229.5 billion CAGR 21.8% Largest Region (2024) North America (39%) By End User Providers (43%) Top Drivers Increasing prevalence of neurological disorders globally. Advancements in AI and machine learning for diagnostics. Growing demand for remote patient monitoring solutions. Top Trends Integration of digital biomarkers in clinical trials. Rise of personalized digital therapeutics (DTx). Focus on consumer-centric neurological wellness applications. Top Challenges Data privacy and security concerns with sensitive health information. Ensuring equitable access to digital health technologies. Navigating complex regulatory and reimbursement landscapes. Virtual Care Platforms are Erasing Distances in Neurological Patient Management Telemedicine is dismantling traditional barriers to neurological care with remarkable speed in the digital health in neurology market. Virtual consultations and remote patient monitoring (RPM) are now standard practice, offering convenience and enhanced oversight. A 2024 survey of pediatric epilepsy providers found 67.9% of their centers now use video visits exclusively for telehealth. A vast majority, 83%, believe these platforms provide more equitable healthcare access. The removal of transportation barriers stands out as a significant driver for teleneurology adoption in 2024. Projections show that by 2025, over 71 million Americans will use some form of RPM service. The utility of telehealth is undeniable. The 2024 study also showed that 92.5% of pediatric epilepsy providers use it for reviewing test results, while 96.2% use it to discuss treatment plan changes. The financial and clinical impact is staggering. The telestroke services market is projected to reach USD 1.99 billion by 2025, with cloud-based platforms dominating 85.3% of that market. A lifetime analysis of a telestroke program revealed an average societal cost saving of $1,526 per patient. Patients also experienced an incremental gain of 0.45 quality-adjusted life years (QALYs). A separate hub-and-spoke telestroke network model demonstrated a lifetime cost saving of $1,436 per patient and a 0.02 QALY gain. A 5-year model of one such network projected an annual cost saving of $358,435 for the entire system, with each spoke hospital saving an estimated $109,080 annually. Ultimately, implementing a telestroke program was associated with a reduction of 101 nursing home residents per 10,000 patients. The digital health in neurology market is clearly benefiting from these efficiency gains. Wearable Technology Unleashes a Continuous Stream of Actionable Patient Data Wearable sensors and mobile health applications are fundamentally changing patient monitoring. They provide a continuous flow of real-world data, empowering both patients and clinicians. The digital health in neurology market is leveraging these tools for proactive disease management. In Parkinson's disease, Rune Labs' StrivePD platform saw its user network expand by 56% in 2024. A nine-month pilot study of the platform involving 138 patients yielded impressive results. Participants experienced a 42% reduction in emergency room visits and an 18% reduction in time needed with movement disorder specialists. The behavioral impact was also significant, with 90% of users increasing their exercise levels and 80% showing improved medication adherence. Rune Labs' 2024 research is powered by a rich dataset from over 1,000 Parkinson's patients using the platform. The momentum extends to other conditions as well. As of 2025, the global market for epilepsy monitoring devices is projected to be valued at an impressive USD 582.3 million. Artificial Intelligence Is Driving a New Era of Diagnostic Precision Artificial intelligence (AI) is supercharging diagnostic capabilities within digital health in neurology market. Machine learning algorithms can analyze complex medical data with unprecedented speed and accuracy. For Parkinson's disease, a condition where early diagnosis is challenging, a new AI software called Automated Imaging Differentiation for Parkinsonism (AIDP) has demonstrated the ability to increase diagnostic precision to beyond 96%. This is a monumental leap compared to the current diagnostic accuracy of 55% to 78% within the first five years. A systematic review of 127 studies on AI-driven Parkinson's diagnosis found accuracy rates consistently ranging from 78% to 96%. An experimental multimodal AI diagnostic framework achieved a 94.2% accuracy in detecting early-stage disease. A deep-learning model analyzing medical and prescription data from 820 Parkinson's patients achieved a diagnostic accuracy of 0.937 when using data from three years preceding diagnosis. When analyzing an even earlier period (3-6 years before diagnosis), the model's accuracy improved to 0.922 with the inclusion of medication data. The trend extends to other conditions, with the US FDA clearing the NeuroQuant 5.0 software, an AI-powered tool for assessing MRI scans of patients being treated for Alzheimer's disease. These advancements are a cornerstone of the digital health in neurology market. Immersive Virtual Reality Therapies Are Redefining Neurorehabilitation Possibilities Virtual Reality (VR) is creating highly engaging and effective therapeutic environments for neurological recovery. The technology is proving particularly useful for patients recovering from stroke, brain injuries, and amputations. In a groundbreaking clinical trial for phantom limb pain, a VR treatment requiring leg movements led to a 39.6% pain reduction among seven participants with lower-limb amputations. Even a distractor VR treatment without leg movements in the same study resulted in a notable 28% decrease in pain. This early success has prompted an expansion of the proof-of-concept study, which initially involved eight subjects with below-knee amputations, to a larger sample size. These immersive solutions represent a high-growth segment within the broader digital health in neurology market, offering new hope for patients undergoing difficult rehabilitation journeys. Digital Biomarkers Are Accelerating the Pace of Neurological Clinical Research Digital biomarkers are revolutionizing how researchers track disease progression and treatment efficacy. Collected via sensors and mobile devices, these objective data points provide a high-frequency view of a patient's condition. Their impact on clinical trial efficiency is profound in the digital health in neurology market. A trial simulation for a hypothetical Parkinson's digital biomarker showed it could lead to a 55.7% reduction in the number of subjects needed for a one-year trial if it detected disease progression just 1.5 times faster than standard assessments. The same simulation indicated that a digital biomarker with a 0.5-fold reduced standard deviation could allow for a trial with 70.0% fewer subjects per arm. Companies are actively building a presence in this space. As of 2024, Rune Labs, a key player focused on digital biomarkers for Parkinson's, had already participated in 15 scientific conferences to share its findings. Robust Investment and a Dynamic Competitive Landscape Signal Strong Market Confidence The financial community is taking notice of the immense potential in neurotechnology. Venture capital and strategic investments are flowing into the digital health in neurology market, fueling innovation. In 2024, European tech companies raised over €1.1 billion in seed funding, with total funding for startups reaching $51 billion. Healthcare and biotechnology was the leading investment sector, attracting over $11 billion. The median pre-seed funding round in Europe grew by 15.7% in the second half of 2024 to €870,000. Specific deals highlight this trend. In October 2024, iGent AI secured a €7.6M seed round, Nomos raised a €1.9M pre-seed round, and In Parallel secured €2.78 million. The competitive landscape is equally dynamic. Blackrock Neurotech received a massive $200 million investment from Tether in 2024, valuing the company at approximately $350 million. Its NeuroPort Array system, priced at over half a million dollars, has been sold to several dozen hospitals. Blackrock Neurotech's estimated annual revenue is $60.7 million, with an estimated revenue per employee of $306,778. Before the latest investment, the company had already raised $50 million and had seen early revenue grow from approximately $700,000 to $3.5 million. Meanwhile, Rune Labs announced a strategic $12 million investment round in 2024, bringing its total funding to $42 million. Its StrivePD platform is also being used in a care management program with Kaiser Permanente. Customize the Data Scope to Match Your Objectives: Evolving Regulations and Emerging Technologies Are Charting the Industry's Future The future of the digital health in neurology market is being shaped by evolving regulatory frameworks and next-generation technologies. Regulators are adapting to the unique nature of software-based medical devices. As of September 2023, Japan had approved only three therapeutic apps. To accelerate innovation, Japan's PMDA set a six-month target review time for priority Software as a Medical Device (SaMD) products as of January 2024. A new two-stage approval system for SaMD was also expected in 2024. Patient engagement is another critical factor. A Mayo Clinic study of its RPM program found a patient engagement rate over 78%. A latest report published in 2025 found that 62% of healthcare leaders in the digital health in neurology market believe Generative AI holds the highest potential for improving patient engagement. Indeed, a 2025 survey revealed 51% of people have already used Generative AI to help diagnose symptoms. Looking ahead, Brain-Computer Interfaces (BCIs) represent the next frontier. The global BCI market was valued at USD 2.3 billion in 2024 and is expected to soar to USD 4.5 billion by 2029. Pioneers like Blackrock Neurotech, with over 40 patients already implanted with their Digital Health In Neurology Market Key Players: AdvancedMD, Inc. Akili, Inc. AppliedVR, Inc. BigHealth Blackrock Neurotech. Cognivive, Inc. Neofect Co, Ltd Omada Health Inc. Proteus Digital Health, Inc. Teladoc Health, Inc. Other Prominent Players Key Market Segmentation: By Component Software Hardware Services By End-use Patients Providers Payers Others By Region North America Europe Asia Pacific Middle East & Africa South America Need a Detailed Walkthrough of the Report? Request a Live Session: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in to access your portfolio
